Apex Biologix Closes a Strategic Financing Round with RevTek Capital

APEX Biologix

Financing from RevTek Capital Fuels Accelerated Growth of Apex Biologix

APEX Biologix

PHOENIX, ARIZONA, UNITED STATES, March 24, 2025

Apex Biologix is a revolutionary force in regenerative medicine.

Apex Biologix delivers cutting-edge solutions that empower physicians and transform patient care. Founded in 2014, this innovative company has rapidly become a leader in the industry, offering a seamless ecosystem of advanced therapeutic devices and supplies.

At the heart of Apex Biologix’s groundbreaking portfolio is the XCELL PRP System, a game-changing solution that delivers unparalleled platelet concentration with breathtaking ease of use. This extraordinary system produces both leukocyte-rich and leukocyte-poor PRP, providing unmatched flexibility for diverse medical applications.

With a relentless focus on innovation, Apex Biologix continues to push the boundaries of regenerative medicine. Its FDA-cleared products, including the XCELL Bone Marrow Concentrating system, showcase the company’s commitment to excellence and regulatory compliance.

Apex Biologix’s visionary approach extends beyond product development. They offer comprehensive educational workshops and marketing resources, empowering practitioners to develop dynamic and engaging regenerative medicine practices. This holistic strategy has propelled Apex Biologix to the forefront of the industry, making it the go-to partner for physicians seeking to harness the transformative power of autologous biologics.

For more information about Apex Biologix and its mission to empower physicians and transform patient care, click here: apexbiologix.com

RevTek Capital Fuels Apex Biologix’s Growth

RevTek Capital recognized the immense potential of Apex Biologix’s full offering of products and services. The recent financing round is a testament to RevTek Capital’s commitment to supporting businesses in redefining and extending their industry profile. Creating exceptional results and value is the mission of every team member.

Scott Peters, CEO and founder of RevTek Capital, expressed his enthusiasm for the relationship:

“Apex Biologix is committed to delivering high-quality products and services to empower physicians and transform patient care. We are very excited to be a part of their exceptional contributions and growth.”

About RevTek Capital

RevTek Capital is a leading strategic debt funding source for companies with predictable recurring revenue. We’ve raised rounds, managed burn, and hit milestones. Now we help founders like you do the same. We leverage our years of early-stage lending and investing experience to provide customized credit solutions to growing companies with predictable recurring revenue/subscription-based businesses. Our goal is to help entrepreneurs grow their business and preserve equity while maximizing enterprise value for all stakeholders. We are the alternative to venture capital.

RevTek’s focus is providing $2MM to $30MM+ for growing companies with $3MM to $75MM in predictable annual recurring revenue. Motivating management teams and allowing investors to maximize investment returns is a key objective. RevTek’s process is always relationship driven and our long-term lending strategy has proven effective for companies in our portfolio.

Be assured that by doing business with RevTek Capital, you are doing business with one of the strongest strategic debt funding sources in the lending market. We have earned a strong reputation, reinforcing the value we deliver and continuity for funding the ongoing growth of the companies we serve.

Funding Solutions from RevTek Capital

If you are looking to obtain growth capital or complete an acquisition, contact us today.

We don’t want to own your business.

We help you grow your business.